We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Anastrozole and Letrozole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00762294
Recruitment Status : Completed
First Posted : September 30, 2008
Last Update Posted : December 15, 2011
Connecticut Breast Health Initiative
Information provided by (Responsible Party):
Pamela Taxel, University of Connecticut Health Center

Brief Summary:

Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer. However, because these medications produce a marked reduction in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures in postmenopausal women treated with these agents. Indeed, substantial bone loss has been reported in several large clinical trials of AIs. Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive. Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach. A better approach might be to select women at highest risk of bone loss and only treat them with antiresorptive agents.

The proposed pilot study will evaluate women who receive anastrozole or letrozole therapy, are receiving adequate amounts of calcium and vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover markers correlate with bone loss at one year. If data from this pilot protocol support our hypothesis, then we would propose a larger trial to confirm it. The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.

Condition or disease
Breast Cancer

Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study
Study Start Date : May 2007
Primary Completion Date : December 2011
Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Women treated for breast cancer who will be starting Arimidex or Femara

Primary Outcome Measures :
  1. bone density [ Time Frame: baseline, 6 months, 12 months ]

Secondary Outcome Measures :
  1. bone markers [ Time Frame: baseline, 1 month, 3 month, 6 month, 12 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women receiving treatment for breast cancer, who will be starting Arimidex or Femara

Inclusion Criteria:

  • Postmenopausal women with diagnosis of breast cancer - have not started Arimidex or Femara yet, but will be starting .

Exclusion Criteria:

  • History of metastasis
  • History of chronic kidney
  • Liver GI disease
  • Disorders affecting calcium metabolism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00762294

United States, Connecticut
University of Connecticut HEalth Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
Connecticut Breast Health Initiative
Principal Investigator: Pamela Taxel, MD UConn Health

Responsible Party: Pamela Taxel, Associate Professor of Medicine, University of Connecticut Health Center
ClinicalTrials.gov Identifier: NCT00762294     History of Changes
Other Study ID Numbers: 07-043-2
GCRC # 644
First Posted: September 30, 2008    Key Record Dates
Last Update Posted: December 15, 2011
Last Verified: December 2011

Keywords provided by Pamela Taxel, University of Connecticut Health Center:
breast cancer
bone health

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal